				<section class="content container">
					<p class="boxed blue">ABILIFY<sup>&reg;</sup> (aripiprazole) is indicated for the acute and maintenance treatment of manic or mixed episodes associated with Bipolar I Disorder as an adjunct to lithium or valproate in adults</p>
					<h6>Unique pharmacology sets <a href="#">ABILIFY<sup>&reg;</sup></a> apart</h6>
					<h6 style="margin-top:.2em;font-size:1.3em;"><a href="#">ABILIFY</a> proposed mechanism of action (MOA)*</h6>
					<img src="http://placehold.it/600x400" style="margin-bottom:2em;">
					<div style="width:60%;margin:1em auto;">
						<ul class="content">
							<li>Aripiprazole exhibits high affinity for dopamine D<sub>2</sub> and D<sub>3</sub>, serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors, moderate affinity for dopamine D<sub>4</sub>, serotonin 5-HT<sub>2C</sub> and 5-HT<sub>7</sub>, alpha1-adrenergic and histamine H<sub>1</sub> receptors, and moderate affinity for the serotonin reuptake site. Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors.</li>
						</ul>
						<p><strong>Standard Mood Stabilizer therapy:</strong></p>
						<ul class="content">
							<li>The mechanism of lithium is hypothesized to alter sodium transport in nerve and muscle cells and effects a shift toward intraneuronal metabolism of catecholamines<sup>3</sup></li>
							<li>The mechanism of valproate is hypothesized to inhibit sodium and/or calcium channel activity, thereby enhancing gamma-aminobutyric acid (GABA) inhibitory action and reducing glutamate excitatory action<sup>4</sup></li>
						</ul>
					</div>
					<h6>Proposed mechanism of action (MOA)*</h6>
					<h6 style="margin-top:.2em;font-size:1.3em;">Example of dopamine partial agonist activity<sup>4</sup></h6>
					<img src="http://placehold.it/980x600">
					<div style="width:60%;margin:1em auto;">
						<h5>Pharmacodynamics and pharmacokinetics</h5>
						<ul class="content">
							<li>The efficacy of ABILIFY may be mediated through a combination of partial agonist activity at D<sub>2</sub> and 5-HT<sub>1A</sub> receptors and antagonist activity at 5-HT<sub>2A</sub> receptors</li>
							<li>The mean elimination half-lives of aripiprazole and dehydro-aripiprazole are 75 hours and 94 hours, respectively</li>
						</ul>
						<p>*The MOA of ABILIFY, as with other drugs having efficacy in MDD and bipolar disorder, is unknown.</p>
					</div>
					<h5 style="width:60%;margin:2em auto 0">Warning on Suicidality and Antidepressant Drugs</h5>
					<p style="width:60%;margin:0 auto 1em;"><strong>Children, adolescents, and young adults taking antidepressants for Major Depressive Disorder (MDD) and other psychiatric disorders are at increased risk of suicidal thinking and behavior. See Full Prescribing Information for complete Boxed WARNING.</strong></p>
				</section>
			
				<?php include '../inc/isi.php'; ?>

				<section class="references container" id="references">
					<p><strong>References:</strong></p>
					<ol class="reference">
						<li>Burstein ES, Ma J, Wong S, et al. Intrinsic efficacy of antipsychotics at human D<sub>2</sub>, D<sub>3</sub>, and D<sub>4</sub> dopamine receptors: identification of the clozapine metabolite <em>N</em>-desmethylclozapine as a D<sub>2</sub>/D<sub>3</sub> partial agonist. <em>J Pharmacol Exp Ther</em>. 2005;315(3):1278-1287.</li>
						<li>Tadori Y, Forbes RA, McQuade RD, Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D<sub>3</sub> receptors. <em>Eur J Pharmacol</em>. 2008;597(1-3):27-33.</li>
						<li>Eskalith [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2003.</li>
						<li>Stahl SM. <em>Essential Psychopharmacology: Neuroscientific Basis and Practical Applications</em>. 2nd ed. Cambridge, United Kingdom: Cambridge University Press; 2000.</li>
					</ol>
				</section>